Drug Approval | February 21, 2025
GSK's Nucala application for COPD accepted for review in China
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
YESINTEK, is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease
IMCD India’s innovative formulations bring the Skinification trend to life with cutting-edge solutions across beauty and personal care
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
ALPLA is going to manufacture high-quality plastic bottles, preforms, matching closures and injection-molded parts in Chachoengsao using all core technologies
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
The company has withdrawn all litigation against Vikas Lifecare Limited post withdrawal of the Alwar Case by VLL
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
Branded formulation business continues to perform well across domestic and export markets
Subscribe To Our Newsletter & Stay Updated
